Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors.

Berube BJ, Russell D, Castro L, Choi SR, Narayanasamy P, Parish T.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02661-18. doi: 10.1128/AAC.02661-18. Print 2019 Jun.

2.

Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus.

Berube BJ, Castro L, Russell D, Ovechkina Y, Parish T.

Front Microbiol. 2018 Oct 10;9:2417. doi: 10.3389/fmicb.2018.02417. eCollection 2018.

3.

Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.

Berube BJ, Parish T.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01677-17. doi: 10.1128/AAC.01677-17. Print 2018 Jan.

4.

Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.

Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T.

ACS Infect Dis. 2017 Dec 8;3(12):898-916. doi: 10.1021/acsinfecdis.7b00112. Epub 2017 Oct 31.

5.

Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Berube BJ, Murphy KR, Torhan MC, Bowlin NO, Williams JD, Bowlin TL, Moir DT, Hauser AR.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01202-17. doi: 10.1128/AAC.01202-17. Print 2017 Nov.

6.

Pseudomonas aeruginosa: breaking down barriers.

Berube BJ, Rangel SM, Hauser AR.

Curr Genet. 2016 Feb;62(1):109-13. doi: 10.1007/s00294-015-0522-x. Epub 2015 Sep 25. Review.

7.

The psmα locus regulates production of Staphylococcus aureus alpha-toxin during infection.

Berube BJ, Sampedro GR, Otto M, Bubeck Wardenburg J.

Infect Immun. 2014 Aug;82(8):3350-8. doi: 10.1128/IAI.00089-14. Epub 2014 May 27.

8.

Tissue-specific patterning of host innate immune responses by Staphylococcus aureus α-toxin.

Becker RE, Berube BJ, Sampedro GR, DeDent AC, Bubeck Wardenburg J.

J Innate Immun. 2014;6(5):619-31. doi: 10.1159/000360006. Epub 2014 May 10.

9.

Targeting Staphylococcus aureus α-toxin as a novel approach to reduce severity of recurrent skin and soft-tissue infections.

Sampedro GR, DeDent AC, Becker RE, Berube BJ, Gebhardt MJ, Cao H, Bubeck Wardenburg J.

J Infect Dis. 2014 Oct 1;210(7):1012-8. doi: 10.1093/infdis/jiu223. Epub 2014 Apr 16.

10.

Staphylococcus aureus α-toxin: nearly a century of intrigue.

Berube BJ, Bubeck Wardenburg J.

Toxins (Basel). 2013 Jun;5(6):1140-66. Review.

11.

Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Quenee LE, Berube BJ, Segal J, Elli D, Ciletti NA, Anderson D, Schneewind O.

Vaccine. 2010 Feb 17;28(7):1870-6. doi: 10.1016/j.vaccine.2009.11.076. Epub 2009 Dec 10.

12.

YopR impacts type III needle polymerization in Yersinia species.

Blaylock B, Berube BJ, Schneewind O.

Mol Microbiol. 2010 Jan;75(1):221-9. doi: 10.1111/j.1365-2958.2009.06988.x. Epub 2009 Dec 7.

13.

Impassable YscP substrates and their impact on the Yersinia enterocolitica type III secretion pathway.

Riordan KE, Sorg JA, Berube BJ, Schneewind O.

J Bacteriol. 2008 Sep;190(18):6204-16. doi: 10.1128/JB.00467-08. Epub 2008 Jul 18.

Supplemental Content

Loading ...
Support Center